Article
Nintedanib inhibits the VEGFR-ERK signaling pathway in human KRAS-mutated cancer cells.
Cell death & disease - 23 Jun 2026
Karnan Sivasundaram, Ota Akinobu, Hasan Muhammad Nazmul, Hyodo Toshinori, Jahan Nushrat, Murakami Hideki, Shihan Md Towhid Ahmed, Hanamura Ichiro, Quang Vu Lam, Riku Miho, Ito Hideaki, Kaneko Yoshifumi, Lin Yinzhi, Wahiduzzaman Md, Rahman Md Lutfur, Inaguma Shingo, Matsui Takuya, Konishi Hiroyuki, Tsuzuki Shinobu, Hosokawa Yoshitaka
Abstract excerpt
KRAS mutations are significant drivers in various cancers, and existing drug discovery attempts targeting these mutations have largely been unsuccessful, emphasizing the need for more effective therapies. In this study, the screening library, which contains 1,374 chemical compounds, identified nintedanib, a VEGFR inhibitor, as exerting a potent and selective antiproliferative effect against KRAS-mutant cells,...
Read the complete abstract on PubMedTopics
- Humans
- Animals
- Proto-Oncogene Proteins p21(ras)
- Indoles
- Cell Line, Tumor